Abstract
Bevacizumab (Avastin), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), demonstrates improved survival when combined with chemotherapy in the treatment of metastatic colorectal cancer (mCRC) patients. Bowel perforation is a serious complication of unknown etiology associated with the use of bevacizumab. Here we report three cases of metastatic colorectal cancer patients, who, after receiving chemotherapy regimen in combination with bevacizumab treatment, were found suffering from intestinal perforation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
